Novartis hopes Seretide-topping data can push docs toward Ultibro


If Novartis wants to be a respiratory giant in Europe, it’s going to have to weasel market share away from GlaxoSmithKline. Now it has some new data it’s hoping can help on that front.

Sunday, the New England Journal of Medicine published head-to-head data showing that the pharma giant’s Ultibro Breezhaler topped GSK’s Seretide--known as Advair in the U.S.--at preventing exacerbations in patients with chronic obstructive pulmonary disease (COPD)--which can lead to hospitalization and even death, Novartis pointed out.

"Reducing exacerbations is absolutely critical to improve outcomes and quality of life for COPD patients," Vasant Narasimhan, the Swiss drugmaker’s CMO, said in a statement. The study “has clearly shown that Ultibro Breezhaler is superior to the current standard of care in reducing exacerbations, marking a shift away from therapies containing steroids for the optimal treatment of COPD patients."

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Or so Novartis hopes. While Seretide has taken a beating over the last couple years on new competition and payer pressure--sales sank 18% in Europe last year--it still raked in £1.01 billion ($1.46 billion) in 2015 sales on the continent. And that’s a far cry from the $260 million Ultibro--a steroid-free LAMA/LABA combo drug--churned out during the same period.

And Glaxo itself has shown that it isn’t easy to propel doctors--used to steroid-containing ICS/LABA meds such as Seretide--toward the newer LAMA/LABAs. Glaxo has had trouble breathing life into its own contender, Anoro, and CEO Andrew Witty noted on the company’s Q1 conference call that physicians are “taking a long time to change habits” when it comes to prescribing.

Novartis, though, thinks it has what it takes to clear that hurdle--and in the meantime, it's looking at fellow new respiratory products Onbrez Breezhaler and Seebri Breezhaler to chip in, too.

"I think we really have a chance to become one of the market leaders in respiratory medicine, and I would see us in most markets doing that ourselves," Novartis pharma chief David Epstein has said of ex-U.S. sales.

- read Novartis' release

Special Report: The 10 best-selling drugs of 2013 - Advair/Seretide

Related Articles:
GSK finally has Breo where it wants it--just in time for Advair copies​
GSK execs, analysts talk up a turnaround as Q1 sales, profits beat estimates​
Boehringer gets respiratory boost with batch of Spiolto nods in EU​
For Novartis' respiratory ambitions, it's a tale of 'two worlds'

Suggested Articles

Wall Street analysts are worried that generics price erosion in the U.S. is taking more of a toll on Sandoz than it is on its competitors.

Takeda sells €1.5 billion European drugs; top Indian drugmakers expand in China; Eisai moves closer to a quick Alzheimer’s blood test.

For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.